Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?

Abstract:

:Obstructive sleep apnoea (OSA) is characterized by repetitive interruptions of breathing, causing Chronic Intermittent Hypoxia (CIH) that can be involved in the development and progression of cardiovascular diseases. There is evidence showing a close relationship between OSA and atherosclerosis, even in patients who do not show co-morbidities such as hypertension, diabetes, high levels of lowdensity lipoprotein cholesterol (LDL-C), cigarette smoking and obesity, which can activate the endothelium. This endothelium activation due to CIH and specific to OSA seems to be dependent on a different pathway. The current first line therapy for OSA is the application of the continuous positive airway pressure (CPAP), but it alone is not enough to reduce cardiometabolic risk in patients with OSA. In contrast, statins, via their pleiotropic property, might be able to change inflammation and early atherosclerosis, lipid profile and cardiovascular outcomes in OSA. The role of statins in OSA patients with or without any co-morbidities could potentially prevent coronary vascular risk and stroke and in the future, represent an additional treatment option along with CPAP therapy. Strengthening the prevention strategies against atherosclerosis in OSA should be one of the focal aims for healthcare programs of the future.

journal_name

Curr Vasc Pharmacol

authors

Toraldo DM,Benedetto M,Conte L,De Nuccio F

doi

10.2174/1570161114666161007164112

subject

Has Abstract

pub_date

2017-01-01 00:00:00

pages

5-9

issue

1

eissn

1570-1611

issn

1875-6212

pii

CVP-EPUB-78837

journal_volume

15

pub_type

杂志文章,评审
  • Gene-lifestyle and gene-pharmacotherapy interactions in obesity and its cardiovascular consequences.

    abstract::Obesity is a highly prevalent complex trait that raises the risk of other chronic diseases such as type 2 diabetes, certain cancers, sleep apnea, and cardiovascular disease, and shortens lifespan. Clinical intervention studies focused on weight loss and epidemiological studies of obesity indicate that genetic variatio...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111796197233

    authors: Franks PW,Poveda A

    更新日期:2011-07-01 00:00:00

  • Metabolic Adaptations to Pregnancy in Healthy and Gestational Diabetic Pregnancies: The Pancreas - Placenta Axis.

    abstract::Normal pregnancy is associated with increased insulin resistance as a metabolic adaptation to the nutritional demands of the placenta and fetus, and this is amplified in obese mothers. Insulin resistance is normally compensated for by an adaptive increase in pancreatic β-cell mass together with enhanced glucose-stimul...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161118666200320111209

    authors: Szlapinski SK,Hill DJ

    更新日期:2021-01-01 00:00:00

  • Cardiovascular diseases and the nitric oxide pathway.

    abstract::Fifteen years after its discovery, NO has fully reached an established position in physiology, medicine and therapeutics. It is difficult to find a biological function or a pathological condition where NO does not play a relevant role. Discoveries in the NO field have historically evolved from cardiovascular research,...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161033476637

    authors: Llorens S,Nava E

    更新日期:2003-10-01 00:00:00

  • The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases.

    abstract::Oxidative stress has been linked to the origin and progression of cardiovascular diseases. Nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase is a multi-component, NADPH-dependent enzyme that generates superoxide anion in the presence of molecular oxygen. The enzyme has been identified and chara...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016108784911984

    authors: Yu J,Weïwer M,Linhardt RJ,Dordick JS

    更新日期:2008-07-01 00:00:00

  • Clinical management of the cardiovascular failure in sepsis.

    abstract::Cardiovascular failure in sepsis involves a combination of hypovolemia, decreased vascular tone, myocardial depression and microcirculatory alterations. Fluids represent the first line therapeutic intervention, with controversy regarding the type of fluid. Recent data indicate that albumin is safe and might even be be...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: De Backer D,Scolletta S

    更新日期:2013-03-01 00:00:00

  • Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk.

    abstract::Biomarkers are used in medicine to facilitate diagnosis, assess risk, direct therapy and determine efficacy of treatment. Sensitivity and specificity are essential in order for a biomarker to be useful. Brain natriuretic peptide (BNP) and C-reactive protein (CRP) are considered biomarkers of cardiovascular disease. Ho...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016107779317251

    authors: Miller VM,Redfield MM,McConnell JP

    更新日期:2007-01-01 00:00:00

  • Paraoxonase-1: Characteristics and Role in Atherosclerosis and Carotid Artery Disease.

    abstract::Paraoxonase-1 (PON-1) is a calcium-dependent enzyme that is synthesized in the liver and then secreted in blood where it is bound to high density lipoprotein (HDL). PON-1 is a hydrolase with a wide range of substrates, including lipid peroxides. It is considered responsible for many of the antiatherogenic properties o...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161115666171129212359

    authors: Lioudaki S,Verikokos C,Kouraklis G,Ioannou C,Chatziioannou E,Perrea D,Klonaris C

    更新日期:2019-01-01 00:00:00

  • Biochemical strategies to anticoagulation: a comparative overview.

    abstract::Hypercoagulability is widely associated with sepsis, inflammation, diabetes, cancers, aging, and many pathological conditions, resulting in life-threatening disseminated intravascular coagulation (DIC), venous thrombosis, thromboembolism, cardiovascular complications, or even deadly multiple organ failure. Relieving c...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161043385673

    authors: Chu AJ

    更新日期:2004-07-01 00:00:00

  • Regulation of blood flow by prostaglandins.

    abstract::Prostaglandins (PGs) belong to the family of prostanoids together with thromboxanes and are produced mainly from arachadonic acid by the enzyme cyclooxygenase. PGs are known to stimulate platelet aggregation, mediate inflammation and edema, play a role in bone metabolism and in biological adaptation of connective tiss...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161043476410

    authors: Boushel R,Langberg H,Risum N,Kjaer M

    更新日期:2004-04-01 00:00:00

  • Editorial: aliskiren/amlodipine single-pill combinations: more evidence in favour of combination formulations for the treatment of hypertension.

    abstract::In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively. ...

    journal_title:Current vascular pharmacology

    pub_type: 评论,社论

    doi:10.2174/157016112803520783

    authors: Katsiki N,Athyros VG,Mikhailidis DP,Karagiannis A

    更新日期:2012-11-01 00:00:00

  • Renalase is removed by kidneys and during dialysis - excess related to CKD complications?

    abstract:BACKGROUND:The most common complications of chronic kidney disease (CKD) are hypertension and cardiovascular (CV) disorders. Renalase is produced and released by the kidney and also cardiomyocytes. Renalase deficiency was claimed to be responsible for hypertension and CV complication in CKD. There are contradictory dat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161113666141217141805

    authors: Malyszko J,Koc-Zorawska E,Zorawski M,Kozminski P,Zbroch E,Rysz J,Banach M,Malyszko JS

    更新日期:2015-01-01 00:00:00

  • Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- pill combinations in patients with an inadequate response to aliskiren monotherapy.

    abstract::Many patients with hypertension will require multiple antihypertensive drugs to achieve blood pressure (BP) control. This double-blind study evaluated the efficacy and safety of aliskiren/amlodipine single-pill combinations (SPCs) in patients with mild-to-moderate hypertension who were non-responsive to aliskiren mono...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2174/157016112803520765

    authors: Glorioso N,Thomas M,Troffa C,Argiolas G,Patel S,Baek I,Zhang J

    更新日期:2012-11-01 00:00:00

  • Occurrence and clinical impact of microembolic signals (MES) in patients with chronic cardiac diseases and atheroaortic plaques--a systematic review.

    abstract:BACKGROUND:In various cardiac diseases, thrombembolism constitutes a major risk, and in these patients clinically silent microembolic signals (MES) are detectable within the transcranial Doppler frequency spectrum (TCD) of the major brain arteries. MES are already an accepted surrogate parameter of the future risk of s...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016108785909797

    authors: Dittrich R,Ringelstein EB

    更新日期:2008-10-01 00:00:00

  • Impact of immunosuppressive drugs on the development of cardiac allograft vasculopathy.

    abstract::Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110792006923

    authors: Dandel M,Hetzer R

    更新日期:2010-09-01 00:00:00

  • Therapeutic Potential of Modulating microRNAs in Atherosclerotic Vascular Disease.

    abstract::Atherosclerosis (also known as arteriosclerotic vascular disease) is a chronic inflammatory disease of the arterial wall, characterized by the formation of lipid-laden lesions. The activation of endothelial cells at atherosclerotic lesion-prone sites in the arterial tree results in the up-regulation of cell adhesion m...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Araldi E,Chamorro-Jorganes A,van Solingen C,Fernández-Hernando C,Suárez Y

    更新日期:2013-05-13 00:00:00

  • Functional link between adenosine and insulin: a hypothesis for fetoplacental vascular endothelial dysfunction in gestational diabetes.

    abstract::Gestational diabetes mellitus (GDM) is a syndrome compromising the health of the mother and the fetus. Endothelial damage and reduced metabolism of the vasodilator adenosine occur and fetal hyperinsulinemia associated with deficient insulin response and a metabolic rather than mitogenic phenotype is characteristic of ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111797484062

    authors: Guzmán-Gutiérrez E,Abarzúa F,Belmar C,Nien JK,Ramírez MA,Arroyo P,Salomón C,Westermeier F,Puebla C,Leiva A,Casanello P,Sobrevia L

    更新日期:2011-11-01 00:00:00

  • Angiogenetic potential of Ad2/Hif-1α/VP16 after regional application in a preclinical pig model of chronic ischemia.

    abstract:UNLABELLED:Hif-1α, a master regulator of ischemia-responsive gene induction, controls pro-angiogenic gene expression of VEGF-A, flt-1, IGF-1 and erythropoietin, rendering its overexpression an attractive tool for therapeutic neovascularization. Utilizing an adenoviral vector system, we investigated the efficacy of sele...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Hinkel R,Lebherz C,Fydanaki M,Wuchrer A,El-Aouni C,Thormann M,Thein E,Kupatt C,Boekstegers P

    更新日期:2013-01-01 00:00:00

  • The role of infection in carotid plaque pathogenesis and stability: the clinical evidence.

    abstract:INTRODUCTION:Chlamydia pneumoniae was the first pathogen linked with carotid atherosclerotic changes and plaque rupture. Currently, other common pathogens are also under investigation as potential contributors. METHODS:A systematic review of PubMed and Scopus databases was performed. Studies evaluating the infectious ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110793563889

    authors: Makris GC,Makris MC,Wilmot VV,Geroulakos G,Falagas ME

    更新日期:2010-11-01 00:00:00

  • Endothelial dysfunction in cardiac allograft vasculopathy: potential pharmacological interventions.

    abstract::Nowadays long-term outcome of heart transplantation is limited by a peculiar type of coronary atherosclerosis, known as cardiac allograft vasculopathy (CAV). Although the exact pathogenesis of CAV remains unclear, emerging evidence indicates that the endothelium plays a significant role in the onset and progression of...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110790886992

    authors: Osto E,Tona F,De Bon E,Iliceto S,Cella G

    更新日期:2010-03-01 00:00:00

  • Visceral adipose tissue and atherosclerosis.

    abstract::Obesity is a risk factor for complications of atherosclerotic vascular disease such as myocardial infarction and stroke. Recent studies have demonstrated that the vascular risk associated with obesity is correlated particularly with visceral adiposity. These clinical observations indicate that various adipose tissue d...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016109787455680

    authors: Ohman MK,Wright AP,Wickenheiser KJ,Luo W,Eitzman DT

    更新日期:2009-04-01 00:00:00

  • Vitamin D is Related to Markers of Vulnerable Plaque in Acute Myocardial Infarction.

    abstract:BACKGROUND:Vitamin D is a fat soluble vitamin involved in calcium and bone metabolism; recently its deficiency has been related to cardiovascular disease. In cardiac tissue, vitamin D suppresses metalloproteinases (MMPs) expression, enzymes directly associated with vulnerable plaque. OBJECTIVE:To investigate whether t...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161115666170609102506

    authors: Machulsky NF,Barchuk M,Gagliardi J,Gonzalez D,Lombardo M,Escudero AG,Gigena G,Blanco F,Schreier L,Fabre B,Berg G

    更新日期:2018-01-01 00:00:00

  • Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.

    abstract:AIM:To assess the potential differences in the metabolic and cardiovascular disease (CVD) risk between the distinct phenotypes of the Polycystic Ovary Syndrome (PCOS) according to the Rotterdam definition regardless of body mass index (BMI). PATIENTS-METHODS:The study included 300 women; 240 women with PCOS, according...

    journal_title:Current vascular pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.2174/1567201812666150120163025

    authors: Daskalopoulos G,Karkanaki A,Piouka A,Prapas N,Panidis D,Gkeleris P,Athyros VG

    更新日期:2015-01-01 00:00:00

  • Hypertension: quo vadis?

    abstract::High blood pressure (BP) along with smoking habit and lipid disorders are the most important and modifiable risk factors for cardiovascular diseases. However, the prevalence of high BP has grown progressively over time with a progressive increase not only in the absolute number of patients but in the proportion of tho...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016112803520927

    authors: Borghi C

    更新日期:2012-11-01 00:00:00

  • Non-lipid effects of statins: emerging new indications.

    abstract::Statins are beneficial both in the primary and secondary prevention of atherosclerotic vascular disease and acute events in a broad spectrum of patient subgroups. However, the observed clinical benefit with statin therapy is much greater than expected through the reduction of cholesterol levels alone. Clinical and exp...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161043385475

    authors: Yildirir A,Müderrisoglu H

    更新日期:2004-10-01 00:00:00

  • Acute coronary syndromes in patients with chronic kidney disease.

    abstract::Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosi...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161111311050013

    authors: Franczyk-Skóra B,Gluba A,Banach M,Rozentryt P,Poloński L,Rysz J

    更新日期:2013-09-01 00:00:00

  • Commentary on the special issue on the impact of myogenic tone in health and disease.

    abstract::Autoregulation is a vital homeostatic mechanism that helps maintain constant delivery of oxygen to organs despite fluctuations in arteriolar pressure. Autoregulation of blood flow to elevations in pressure is largely mediated by the myogenic response of small arteries and arterioles which constrict in response to elev...

    journal_title:Current vascular pharmacology

    pub_type:

    doi:10.2174/15701611113116660157

    authors: Roman RJ,Van Dokkum RP

    更新日期:2014-01-01 00:00:00

  • Cardiac side effects of chemotherapy: state of art and strategies for a correct management.

    abstract::In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threaten...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111201140327163302

    authors: Perrino C,Schiattarella GG,Magliulo F,Ilardi F,Carotenuto G,Gargiulo G,Serino F,Ferrone M,Scudiero F,Carbone A,Trimarco B,Esposito G

    更新日期:2014-01-01 00:00:00

  • Therapeutic potential of high mobility group box-1 in ischemic injury and tissue regeneration.

    abstract::High-mobility group box-1 (HMGB1) is a nuclear protein that acts as a cytokine when released into the extracellular milieu by necrotic and inflammatory cells, and is involved in inflammatory responses and tissue repair. This protein is released passively during cellular necrosis by almost all cells that have a nucleus...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111797484125

    authors: Biscetti F,Ghirlanda G,Flex A

    更新日期:2011-11-01 00:00:00

  • Cardiovascular toxicity from the perspective of oxidative stress, electron transfer, and prevention by antioxidants.

    abstract::This review demonstrates that oxidative stress, reactive oxygen species, and electron transfer can serve as unifying mechanistic themes for large numbers of cardiovascular toxins, both endogenous and exogenous. Lipid peroxidation is a prevalent insult. Common among the various conditions are atherosclerosis and arrhyt...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161053586912

    authors: Kovacic P,Thurn LA

    更新日期:2005-04-01 00:00:00

  • Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.

    abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the general population. The disease ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma. Several drugs are used in daily clinical practice to manage the disease. However, dat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161115666170621083744

    authors: Imprialos K,Stavropoulos K,Bouloukou S,Kerpiniotis G,Karagiannis A,Doumas M

    更新日期:2018-01-01 00:00:00